Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.

/ Publications / Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.

Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.

Authors: Payne, J. F., Wykoff, C. C., Clark, W. L., Bruce, B. B., Boyer, D. S., & Brown, D. M.
Presented: January 1, 2020
Type: Publications

Background/aims: To evaluate the long-term effects of treat-and-extend dosing of ranibizumab with and without navigated focal laser for diabetic macular oedema (DME).

Related publications and webinars

From Minimally Invasive Procedure to Photocoagulation: Personalized retinal care with Navilas® (Japanese)

  • Type:
  • Presented:February 8, 2024
Priv.-Doz. Dr. med. Yoko Miura

On-Demand Webinar: Navilas in der täglichen Praxis

  • Type:
  • Presented:February 1, 2017
Dr. Bernd Fassebender
  • The treatment strategy and selected parameters presented in content listed here are solely the responsibility of the treating ophthalmologist, who is required to be familiar with the most recent literature/guidelines or recommendations, as well as with the usage of the Navilas Laser System according to the current Operator’s Manual.